News & Trade Shows

News & Trade shows


Biomerica Purchases New Celiac Disease Tests
4/28/2009
 
Biomerica purchases the assets, technology and rights for new Celiac disease tests

Newport Beach, California – April 28, 2009 -- Biomerica, Inc. (OTC BB: BMRA) announced that it has purchased the assets, technology and rights for three new Celiac disease tests from an undisclosed European Company.  The three new products include a test to detect antibodies to tissue Transglutaminase (tTg) and two tests to detect antibodies to Gliaden. Celiac disease affects almost 1% of the U. S. population. That means that as many as 3 million people in the United States are living with celiac disease, and 97% of them are undiagnosed. Until recently, the geographical distribution of celiac disease was thought to be primarily in developed countries, but new epidemiological studies have provided evidence that the disorder is common in other parts of the world as well.  Its prevalence has been estimated to be from 0.4% to 1% of the world’s population.  The National Institute of Diabetes and Digestive and Kidney Diseases (part of the NIH), The American Celiac Disease Alliance and The Celiac Disease Foundation all recommend performing one or more of the type of tests Biomerica has acquired for the diagnosis of Celiac disease.

Celiac disease is an inherited autoimmune disorder that affects the digestive process of the small intestine. When a person who has celiac disease consumes gluten, a protein found in wheat, rye and barley, the individual’s immune system responds by attacking the small intestine and inhibiting the absorption of important nutrients into the body. Undiagnosed and untreated, celiac disease can lead to the development of other autoimmune disorders, as well as osteoporosis, infertility, neurological conditions and in rare cases, cancer.  While there is no known cure for celiac disease, it can be treated by adherence to a gluten-free diet.

“We are pleased to be expanding our gastrointestinal test line to include these new Celiac disease tests,” said Zackary Irani, CEO of Biomerica.   “We believe they are an excellent complement to our current food intolerance tests and are excited about the growth prospects for these products.” The Company is currently transferring the production of these products to Biomerica facilities and estimates that the transfer will be completed before the summer. These products will initially be sold internationally and in the U.S. only after FDA clearance.  The terms of the transaction were not disclosed.

About Biomerica (OTCBB: BMRA)
Biomerica, Inc. (www.biomerica.com) is a global medical technology company, based in Newport Beach, CA.  The Company manufactures and markets advanced diagnostic products used at home, in hospitals, and in physicians’ offices for the early detection of medical conditions and diseases.

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking; such as statements relating to intended launch dates, sales potential, significant benefits, market size, growth of business, favorable positions, expansion, expected orders, leading market positions, anticipated future revenues or production volume of the Company, success of product and new product offerings. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, and accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. The potential risks and uncertainties include, among others, fluctuations in the Company’s operating results due to its business model and expansion plans, downturns in international and or national economies, the Company’s ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company’s dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.